Clinical trial NCT06684379: Study on Safety and Efficacy of Two Doses of PRS CK STORM in the Prevention of COVID-19-Associated Cytokine Storm
Official title: Double-blind, Randomized, Placebo-controlled, Pilot Study to Evaluate the Safety, Tolerability and Efficacy of Two Doses of a Conditioned Medium From a Co-culture of M2-macrophages and Mesenchymal Cells (PRS CK STORM) in the Prevention of COVID-19-associated Cytokine Storm (PRSMA)
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE1
PHASE2
Conditions: SARS-CoV-2
Keywords: SARS-CoV-2 infection
Causing atypical respiratory disease (COVID-19)
2019 Novel Coronavirus
COVID-19 Virus
SARS Coronavirus 2
COVID-19-associated cytokine storm
Lung Diseases
Pneumonia
M2-macrophages
Mesenchymal cells
Lead sponsor: PEACHES BIOTECH
Sponsor class: INDUSTRY
First posted: 2024-11-12
Enrollment: 50
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: SEQUENTIAL
Intervention model description: Subjects will be randomized in blocks; the study will be conducted in 2 parts in sequential groups of two increasing doses of PRS CK STORM (A and B) and consecutively evaluated in 2 sentinel groups of 4 patients. Patients will be randomized to receive treatment in groups of 2, for 5 consecutive days, until 48 hours after the last drug administration (short-term safety follow-up period).
Primary purpose: TREATMENT

Brief summary: The purpose of this clinical trial is to evaluate the safety and tolerability of two doses (dose A and dose B) of Standardized Conditioned Medium Obtained by Coculture of Monocytes and Mesenchymal Stromal Cells (PRS CK STORM) in the prevention of COVID-19-associated cytokine storm in participants with a confirmed diagnosis of SARS-CoV-2 infection, recently hospitalized (less than 3 days) and who have had symptoms for up to a maximum of 10 days prior to screening.

The main questions it aims to answer are:

* Are both doses of PRS CK STORM (dose A and dose B) safe as an intravenous drug to prevent and treat inflammatory processes, such as the cytokine storm associated with severe infectious processes, including COVID-19?
* Are both doses of PRS CK STORM (dose A and dose B) effective as an intravenous drug to prevent COVID-19 associated cytokine storm compared to the control group?
* What are the anti-inflammatory and pro-inflammatory cytokine profiles after treatment with two different doses of PRS CK STORM in participants hospitalized for COVID-19 classified with mild disease severity according to the World Health Organization (WHO) Clinical Progression Scale?

Researchers will compare both doses of PRS CK STORM with the control group to test whether the anti-inflammatory action of PRS CK STORM is safe and effective in treating inflammatory processes, such as the cytokine storm associated with severe infectious processes, including COVID-19. In addition, the anti-inflammatory and pro-inflammatory cytokine profiles after treatment PRS CK STORM compared to placebo group in COVID-19 participants will be also studied.

Detailed description: This is a double-blind, randomized, phase I/II pilot trial study of two doses of PRS CK STORM in hospitalized adult participants with confirmed SARS-CoV-2 infection by RT-PCR. All participants will receive the standard of care for SARS-CoV-2 infection as described in the COVID-19 Patient Management Protocol. Participants who meet the eligibility criteria will be randomized in blocks to reach the 2:2:1 ratio (dose A: dose B: placebo).

This study consists of two parts:

Part 1: Two different doses (A and B) of PRS CK STORM will be evaluated in 2 groups of 4 participants (3:1; PRS CK STORM: placebo). It starts with a first sentinel group of 4 participants who will be assigned to placebo or study drug dose A. First, only 2 participants will randomly be assigned to receive the active treatment of dose A or placebo for 5 consecutive days. These 2 first participants will be followed up to 48h after the last drug administration (short-term safety follow-up period) when a safety assessment will be completed before treating the other 2 participants in this group.

If the study drug is considered safe during the short-term safety assessment planned 48h after the last drug administration, then 2 additional participants will be treated with dose A for 5 consecutive days to complete the first sentinel group of 4 participants. These 2 participants will be followed up to 48h after the last study drug administration before moving to dose B.

After the assessment of data collected follow-up for this first group, a second small sentinel group of other 4 participants will be treated with a higher dosage (dose B) following the same process: firstly, only 2 participants will randomly receive the active treatment of dose B or placebo for 5 consecutive days and then these 2 first participants will be followed up to 48h after.

If the study drug is considered safe during the safety assessment planned 48h after last drug administration, then two additional participants will be treated with dose B for 5 consecutive days to complete the sentinel second group of 4 participants evaluating dose B. These 2 participants will be also followed up to 48h after the last study drug administration before moving to Part 2.

All these 8 participants included in Part 1 will continue in a long-term safety follow-up period until 1 year post treatment.

Part 2: 42 additional participants will be treated for 5 consecutive days. These 42 participants will be randomized to three treatment arms: 17 in the active arm with dose A, 17 participants in the active arm with dose B and 8 participants in the placebo arm. All participants in Part 2 will be followed up to 48h after the last study drug (short-term safety follow-up period). Once all participants treated in Part 2 finished the short-term safety follow-up period (48h after last study drug administration), all data will be verified and statistically analyzed in an interim analysis. All participants will be followed up to 1 year post treatment (long-term safety follow-up period). Therefore, considering the participants enrolled in Part 1 and Part 2 the total number of participants for safety, tolerability and efficacy analysis will be 50 assigned to three different arms (total randomization ratio 2:2:1), 20 participants will receive dose A, 20 participants will receive dose B and 10 participants will receive placebo.

To sum up, considering the participants enrolled in Part 1 and Part 2 the total number of participants for safety, tolerability and efficacy analysis will be 50 assigned to three different arms (total randomization ratio 2:2:1), 20 participants will receive dose A of PRS CK STORM, 20 participants will receive dose B of PRS CK STORM and 10 participants will receive placebo.

The estimated duration of the study for individual participants will be 12 months (screening: 3 days, treatment period: 5 days, short-term safety follow-up period: 2 days after the last drug intake and long-term safety follow-up period: up to 48 weeks from randomization).

It is hypothesized that both doses of PRS CK STORM for intravenous administration are safe, well tolerated and clinically beneficial versus placebo for participants with COVID-19-associated cytokine storm.

Eligibility criteria: Inclusion Criteria:

1. Signed informed consent by the patient or legal representative prior to the initiation of any study-specific procedure.
2. Males and females with a confirmed diagnosis of SARS-CoV-2 infection by positive Reverse Transcription Polymerase Chain Reaction (RT-PCR).
3. Age more than 18 years old at the time of the consent.
4. Participants to be hospitalized or who have been admitted for less than 3 days with a positive RT-PCR result and who have had symptoms up to a maximum of 10 days prior to screening.
5. Female participants must be, either surgically sterilized or at least 1 year postmenopausal (confirmed by follicle-stimulating hormone \[FSH\] more than 20 international units \[Ius\] only for women under 54) or using adequate birth control (hormonal contraception, intrauterine contraceptive device, double barrier methods \[condom with spermicide, diaphragm with spermicide, or condom and diaphragm\]) or sexual abstinence for up to 90 days after the last treatment administration. Male participants must be willing to use barrier contraception (condom) for up to 90 days after the last treatment administration.
6. Participants classified in 4 or 5 score of severity according to WHO clinical progression scale:

Level 4: hospitalized, no oxygen therapy. Level 5: hospitalized, oxygen by mask or nasal prongs.

Exclusion Criteria:

1. Failure to perform screening or baseline examinations.
2. Body Mass Index (BMI) more than or equal to 35.
3. Not confirmed SARS-CoV-2 infection by RT-PCR.
4. Participants who have been previously classified in a higher score than 5 in WHO clinical progression scale
5. Clinically significant, advanced or unstable disease that may interfere with primary or secondary variable evaluations, may bias the clinical assessment, such as:

   1. Liver function test abnormalities or other signs of hepatic insufficiency: Aspartate transaminase (AST), alanine transaminase (ALT) more than 3 per upper limit of the reference range, total bilirubin more than or equal to 2 mg/dL; except for subjects with isolated elevation of indirect bilirubin relating to Gilbert syndrome.
   2. Renal insufficiency (serum creatinine more than 2 mg/dL (more than 150 μmol/L) and creatinine clearance less than 60 (according to Cockcroft-Gault formula).
   3. Myocardial infarction, unstable angina, heart failure within 3 months before screening.
   4. Bradycardia (heartbeat less than 50/min).
   5. Atrioventricular block (type II / Mobitz II and type III), congenital long QT syndrome, sinus node dysfunction or prolonged QTcF interval (males more than 450 msec and females more than 470 msec using Fridericia's formula: QTc = QT/ RR\^2 ).
   6. Uncontrolled diabetes mellitus (blood glucose level above 500 mg/dL) at the time of admission.
   7. Malignant tumors within the last 5 years except skin malignancies (other than melanoma) or indolent prostate cancer
   8. Metastases.
   9. Human Immunodeficiency Virus (HIV), HBV \[hepatitis B surface antigen (HBs Ag) positive (+), or detected sensitivity on the HBV deoxyribonucleic acid (DNA), polymerase chain reaction (PCR) qualitative test for hepatitis B core antibody (HBc Ab) positive subjects\] or HCV \[HCV ribonucleic acid (RNA) detectable in any subject with positive anti-HCV antibody (HCV Ab)\].
   10. Other serious active viral infections apart from SARS-CoV-2 that are requiring specific antimicrobial treatment.
6. Inability to comply with the study and monitoring procedures.
7. Pregnant and breastfeeding females (pregnancy test positive).
8. Suspected or known history of drug or alcohol abuse.
9. Enrollment in another investigational drug study within 1 month before the screening
10. Subject who has any condition, including any psychological or psychiatric condition, in the opinion of the Investigator, would compromise the safety of the subject or the quality of the data and renders the subject an unsuitable candidate for the study.

Primary outcomes:
measure: Adverse Events (AEs)
timeFrame: Up to 12 months
measure: Serious adverse events (SAEs)
timeFrame: Up to 12 months
measure: Treatment-emergent adverse events (TEAEs)
timeFrame: Up to 12 months
measure: Safety measures: Clinical evaluation through physical examination
timeFrame: Day 7, Day 30, Day 90 and Day 365
measure: Changes from Baseline in vital signs: body temperature
timeFrame: From Day 1 to Day 7, Day 30, Day 90 and Day 365
measure: Changes from Baseline in vital signs: oximetry
timeFrame: From Day 1 to Day 7, Day 30, Day 90 and Day 365
measure: Changes from Baseline in vital signs: Heart rate
timeFrame: From Day 1 to Day 7, Day 30, Day 90 and Day 365
measure: Changes from Baseline in vital signs: Respiratory rate
timeFrame: From Day 1 to Day 7, Day 30, Day 90 and Day 365
measure: Changes from Baseline in vital signs: Diastolic Blood Pressure
timeFrame: From Day 1 to Day 7, Day 30, Day 90 and Day 365
measure: Changes from Baseline in vital signs: Systolic blood pressure
timeFrame: : From Day 1 to Day 7, Day 30, Day 90 and Day 365
measure: Safety measures: electrocardiograms (ECG)
timeFrame: Day 7, Day 30, Day 90 and Day 365
measure: Safety measures: Laboratory results
timeFrame: Day 1, Day 3, Day 6, Day 7, Day 30, Day 90 and Day 365
Secondary outcomes:
measure: Death rate
timeFrame: Day 7, Day 14 and Day 365
measure: Participants who reach 7 score or higher according to World Health Organization (WHO) clinical progression scale
timeFrame: Up to 12 months
measure: Clinical improvement according to World Health Organization (WHO) clinical progression scale
timeFrame: Up to 12 months
measure: Average hospital stays (in days)
timeFrame: Up to 12 months
measure: Participants requiring admission to Intensive Care Unit (ICU)
timeFrame: Up to 12 months
measure: Radiological findings
timeFrame: Day 7 and Day 10 Up to 12 months
measure: Oximetry levels
timeFrame: Up to 12 months
measure: Overall survival (in days)
timeFrame: Up to 12 months
measure: Time to progression (in days)
timeFrame: Up to 12 months
Other outcomes:
measure: Variations in anti-inflamatory cytokine levels
timeFrame: Day 1, Day 3 and Day 6
measure: Variation in pro-inflammatory cytokine levels
timeFrame: Day 1, Day 3 and Day 6
measure: World Health Organization (WHO) Clinical Progression Scale considering risk factors
timeFrame: Up to 12 months
Locations:
city: Fuenlabrada
country: Spain
facility: Hospital Universitario de Fuenlabrada
state: Madrid
Study officials:
affiliation: Hospital Universitario de Fuenlabrada
name: David Bernal, Dr.
role: PRINCIPAL_INVESTIGATOR
affiliation: Hospital Universitario de Fuenlabrada
name: Guillermo Soria Fernández-Llamazares, Dr
role: STUDY_CHAIR
References:
citation: Lapuente JP, Gomez G, Marco-Brualla J, Fernandez P, Desportes P, Sanz J, Garcia-Gil M, Bermejo F, San Martin JV, Algaba A, De Gregorio JC, Lapuente D, De Gregorio A, Lapuente B, Gomez S, Andres MLV, Anel A. Evaluation in a Cytokine Storm Model In Vivo of the Safety and Efficacy of Intravenous Administration of PRS CK STORM (Standardized Conditioned Medium Obtained by Coculture of Monocytes and Mesenchymal Stromal Cells). Biomedicines. 2022 May 8;10(5):1094. doi: 10.3390/biomedicines10051094.
citation: Lapuente JP, Blazquez-Martinez A, Marco-Brualla J, Gomez G, Desportes P, Sanz J, Fernandez P, Garcia-Gil M, Bermejo F, San Martin JV, Algaba A, De Gregorio JC, Lapuente D, De Gregorio A, Lapuente B, Andres MV, Anel A. Cytokine Profile and Anti-Inflammatory Activity of a Standardized Conditioned Medium Obtained by Coculture of Monocytes and Mesenchymal Stromal Cells (PRS CK STORM). Biomolecules. 2022 Mar 31;12(4):534. doi: 10.3390/biom12040534.